A lot of efforts have been made to investigate the prognostic biomarkers including epigenetic markers in cancers, helping to identify high-risk cancer patients who might need adjuvant treatment after surgery. Studies suggest complex genetic and epigenetic profiles of the gastric carcinoma patients, indicating the need for the identification of molecular markers for this tumor type.
Aim of the work: To clarify the role of EMMPRIN (CD147), CD24 and methylation of p16 promoter in genesis and progression of gastric carcinoma.
Material and methods: Expression of Extracellular MMP inducer (CD147) and CD24 was examined immunohistochemically in tissues sections from gastric carcinomas (n=80) and non-cancerous gastric tissues [chronic gastritis with intestinal metaplasia (n=16) and gastric dysplasia(n=20)]. In additon 16 cases of apparently normal gastric tissue were used as control and the expression were compared with clinicopathological parameters of cancer cases including 5-year survival. Methylation frequency of p16 promoter was determined by methylation specific polymerase chain reaction (MPCR)
Results: Both CD147 and CD24 were gradually increased from normal mucosa to carcinomas through metaplastic and dysplastic mucosa of the stomach (P |
